These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10840195)

  • 21. Novel cationic amphiphiles as delivery agents for antisense oligonucleotides.
    DeLong RK; Yoo H; Alahari SK; Fisher M; Short SM; Kang SH; Kole R; Janout V; Regan SL; Juliano RL
    Nucleic Acids Res; 1999 Aug; 27(16):3334-41. PubMed ID: 10454641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery.
    Bochot A; Couvreur P; Fattal E
    Prog Retin Eye Res; 2000 Mar; 19(2):131-47. PubMed ID: 10674705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions.
    Astriab-Fisher A; Sergueev D; Fisher M; Shaw BR; Juliano RL
    Pharm Res; 2002 Jun; 19(6):744-54. PubMed ID: 12134943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cationic liposomes on intracellular trafficking and efficacy of antisense oligonucleotides in mouse peritoneal macrophages.
    Takagi T; Hashiguchi M; Hiramatsu T; Yamashita F; Takakura Y; Hashida M
    J Drug Target; 2000; 7(5):363-71. PubMed ID: 10721798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Slow release and delivery of antisense oligonucleotide drug by self-assembled peptide amphiphile nanofibers.
    Bulut S; Erkal TS; Toksoz S; Tekinay AB; Tekinay T; Guler MO
    Biomacromolecules; 2011 Aug; 12(8):3007-14. PubMed ID: 21707109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes.
    Fattal E; Couvreur P; Dubernet C
    Adv Drug Deliv Rev; 2004 Apr; 56(7):931-46. PubMed ID: 15066753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel non-endocytic delivery of antisense oligonucleotides.
    Dokka S; Rojanasakul Y
    Adv Drug Deliv Rev; 2000 Oct; 44(1):35-49. PubMed ID: 11035196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
    Pakunlu RI; Wang Y; Saad M; Khandare JJ; Starovoytov V; Minko T
    J Control Release; 2006 Aug; 114(2):153-62. PubMed ID: 16889867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.
    Juliano RL; Alahari S; Yoo H; Kole R; Cho M
    Pharm Res; 1999 Apr; 16(4):494-502. PubMed ID: 10227702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Trend in genetic medicine].
    Shoji Y; Mizushima Y
    Nihon Rinsho; 1998 Aug; 56(8):2186-95. PubMed ID: 9750532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes.
    Yamauchi M; Kusano H; Saito E; Iwata T; Nakakura M; Kato Y; Uochi T; Akinaga S; Aoki N
    J Control Release; 2006 Aug; 114(2):268-75. PubMed ID: 16860428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides.
    Akhavein N; Oettinger CW; Gayakwad SG; Addo RT; Bejugam NK; Bauer JD; Do D; Pollock SH; D'souza MJ
    J Microencapsul; 2009 May; 26(3):223-34. PubMed ID: 18666015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects.
    Hu Q; Shew CR; Bally MB; Madden TD
    Biochim Biophys Acta; 2001 Sep; 1514(1):1-13. PubMed ID: 11513800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs.
    Zhang C; Newsome JT; Mewani R; Pei J; Gokhale PC; Kasid UN
    Methods Mol Biol; 2009; 480():65-83. PubMed ID: 19085118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.
    Arora V; Devi GR; Iversen PL
    Curr Pharm Biotechnol; 2004 Oct; 5(5):431-9. PubMed ID: 15544491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspects of the transport and delivery of antisense oligonucleotides.
    Juliano RL; Yoo H
    Curr Opin Mol Ther; 2000 Jun; 2(3):297-303. PubMed ID: 11249624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal targeting of bcl-2 antisense oligonucleotides with enhanced stability into human myeloma cell lines.
    Ollikainen H; Lappalainen K; Jääskeläinen I; Syrjänen S; Pulkki K
    Leuk Lymphoma; 1996 Dec; 24(1-2):165-74. PubMed ID: 9049973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation.
    Clarenc JP; Degols G; Leonetti JP; Milhaud P; Lebleu B
    Anticancer Drug Des; 1993 Feb; 8(1):81-94. PubMed ID: 8476504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.